Alcon saw the highest growth of 1.55% in patent filings and 1.26% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.61% and grants by 1.06%. GlobalData’s DataBook provides a comprehensive analysis of Alcon‘s patent filings and grants. Buy the databook here.
Alcon has been focused on protecting inventions in United States(US) with 67 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 30% filings and 29% grants. The Australia(AU), United States(US), European Patent Office(EPO), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where Alcon is filings its patents. Among the top granted patent authorities, Alcon has 29% of its grants in United States(US), 27% in European Patent Office(EPO) and 26% in Australia(AU).
Carl Zeiss Stiftung and Johnson & Johnson could be the strongest competitors for Alcon
Patents related to healthtech and machine learning lead Alcon's portfolio
Alcon has the highest number of patents in healthtech followed by, machine learning and remote patient monitoring. For healthtech, nearly 25% of patents were filed and 33% of patents were granted in Q2 2024.
Ophthalmic devices related patents lead Alcon portfolio followed by general surgery devices, and image management
Alcon has highest number of patents in ophthalmic devices followed by general surgery devices, image management, intraocular lens (iol), and contact lenses. For ophthalmic devices, nearly 46% of patents were filed and 33% of patents were granted in Q2 2024.
For comprehensive analysis of Alcon's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.